4.6 Article

ProBDNF as an Indicator of Improvement among Women with Depressive Episodes

Journal

METABOLITES
Volume 12, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/metabo12040358

Keywords

mood disorders; depression; bipolar disorder; brain-derived neurotrophic factor; biomarkers

Funding

  1. National Science Center, Poland [2016/23/B/NZ5/02634]
  2. Poznan University of Medical Sciences in Poland [502-20-22196440]

Ask authors/readers for more resources

This study aimed to compare serum levels of BDNF, proBDNF, and S100B before and after treatment for acute depressive episodes and assess their correlation with symptom severity and stress history. The results showed a significant decrease in proBDNF levels after treatment, while BDNF and S100B levels did not change significantly. Thus, a decrease in serum proBDNF levels may be considered a biomarker of recovery from depressive episodes.
Depression is a chronic psychiatric disorder with a heavy socioeconomic burden. Studies on biomarkers are needed to comprehend the pathophysiology of depression and to improve treatment outcomes. Research points to the importance of imbalance between mature brain-derived neurotrophic factor (BDNF) and its precursor, pro-brain-derived neurotrophic factor (proBDNF), in the pathophysiology of mood disorders and the potential neurodegenerative role of calcium-binding protein B (S100B). Our objective was to compare BDNF, proBDNF, and S100B serum levels before and after the treatment of acute depressive episodes and to assess their correlation with the severity of symptoms and history of stress. We also aimed to investigate the differences in BDNF, proBDNF, and S100B levels between depression in the course of bipolar disorder (BD) and major depressive disorder (MDD). We recruited 31 female patients diagnosed with BD or MDD who were hospitalized due to current depressive episodes. The patients had their serum BDNF, proBDNF, and S100B levels evaluated using the ELISA method upon admission and after the symptoms improved, at discharge. We found that proBDNF levels decreased significantly with the treatment (p = 0.0478), while BDNF and S100B levels were not altered significantly. No differences in biochemical parameters between MDD and BD subjects were observed. Consequently, we concluded that a decrease in serum proBDNF levels could be considered a biomarker of recovery from depressive episodes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available